Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC

被引：0
|
作者：
Kim, C. [1 ]
Xi, L. [2 ]
Cultraro, C. [1 ]
Wei, F. [3 ]
Cheng, J. [3 ]
Shafiei, A. [4 ]
Pham, T. [2 ]
Roper, N. [1 ]
Akoth, E. [1 ]
Strom, C. [3 ]
Tu, M. [5 ]
Liao, W. [5 ]
Chia, D. [3 ]
Morris, C. [6 ]
Rajan, A. [1 ]
Bagheri, M. [4 ]
Jones, G. [6 ]
Wong, D. [3 ]
Raffeld, M. [2 ]
Guha, U. [1 ]
机构：
[1] NCI, Thorac & Gi Malignancies Branch, Ccr, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Ccr, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] NIH, Radiol & Imaging Sci, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA
[5] Ezlife Bio Inc, Woodlind Hills, CA USA
[6] Inivata, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-mutant NSCLC; cDNA; Osimertinib;
D O I：
10.1016/j.jtho.2019.08.742
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-27
引用
收藏
页码：S366 / S366
页数：1
相关论文
共 50 条
  • [1] Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma
    Kim, Chul
    Xi, Liqiang
    Cultraro, Constance M.
    Wei, Fang
    Jones, Gregory
    Cheng, Jordan
    Shafiei, Ahmad
    Pham, Trinh Hoc-Tran
    Roper, Nitin
    Akoth, Elizabeth
    Ghafoor, Azam
    Misra, Vikram
    Monkash, Nina
    Strom, Charles
    Tu, Michael
    Liao, Wei
    Chia, David
    Morris, Clive
    Steinberg, Seth M.
    Bagheri, Hadi
    Wong, David T. W.
    Raffeld, Mark
    Guha, Udayan
    CANCERS, 2021, 13 (13)
  • [2] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [3] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [4] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
    Remon, Jordi
    Caramella, Caroline
    Joelet, Cecile
    Lacroix, Ludovic
    Lawson, Andrew
    Smalley, Sarah
    Howarth, Karen
    Gale, Davina
    Rosenfeld, Nitzan
    Green, Emma
    Plagnol, Vincent
    Planchard, David
    Bluthgen, Maria
    Gazzah, Annas
    Pannet, Chloe
    Nicotra, Claudio
    Soria, Jean-Charles
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
  • [5] Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
    Kim, C.
    Xi, L.
    Cultraro, C.
    Pham, T.
    Roper, N.
    Bagheri, M.
    Rajan, A.
    Beeler, J.
    Jones, G.
    Raffeld, M.
    Guha, U.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S478 - S478
  • [6] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [7] Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
    Yamaguchi, Ou
    Kasahara, Norimitsu
    Soda, Hiroshi
    Imai, Hisao
    Naruse, Ichiro
    Yamaguchi, Hiroyuki
    Itai, Miki
    Taguchi, Kohei
    Uchida, Megumi
    Sunaga, Noriaki
    Maeno, Toshitaka
    Minato, Koichi
    Tomono, Hiromi
    Ogawara, Daiki
    Mukae, Hiroshi
    Miura, Yu
    Shiono, Ayako
    Mouri, Atsuto
    Kagamu, Hiroshi
    Kaira, Kyoichi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib
    Ou Yamaguchi
    Norimitsu Kasahara
    Hiroshi Soda
    Hisao Imai
    Ichiro Naruse
    Hiroyuki Yamaguchi
    Miki Itai
    Kohei Taguchi
    Megumi Uchida
    Noriaki Sunaga
    Toshitaka Maeno
    Koichi Minato
    Hiromi Tomono
    Daiki Ogawara
    Hiroshi Mukae
    Yu Miura
    Ayako Shiono
    Atsuto Mouri
    Hiroshi Kagamu
    Kyoichi Kaira
    Scientific Reports, 13
  • [9] Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA
    Remon, J.
    Caramella, C.
    Jovelet, C.
    Lacroix, L.
    Lawson, A.
    Smalley, S.
    Howarth, K.
    Gale, D.
    Green, E.
    Plagnol, V.
    Rosenfeld, N.
    Planchard, D.
    Bluthgen, M. V.
    Gazzah, A.
    Pannet, C.
    Nicotra, C.
    Auclin, E.
    Soria, J. C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 784 - 790
  • [10] Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo Vailati
    Nilsson, Monique B.
    Robichaux, Jacqulyne Ponville
    Boyle, Theresa A.
    Hicks, James Kevin
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie S.
    Zhangx, Jianjun
    Papadimitrakopoulou, Vassiliki
    Gray, Jhanelle Elaine
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345